Search
Allosamidin
go.drugbank.com/drugs/DB04628ExperimentalAllosamidin exhibits extremely potent inhibitory activity against chitinases from a number of sources, particularly from <i>Candida albicans</i>, and can be utilized as potent antifungal agent.
Agatolimod
go.drugbank.com/drugs/DB15018InvestigationalAgatolimod is under investigation in clinical trial NCT00471471 (Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery).
AZD-1386
go.drugbank.com/drugs/DB15333InvestigationalAZD-1386 is under investigation in clinical trial NCT00945178 (Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers).
Sofituzumab vedotin
go.drugbank.com/drugs/DB15349InvestigationalSofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable
Oxelumab
go.drugbank.com/drugs/DB16663InvestigationalOxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).
WP-1301
go.drugbank.com/drugs/DB17702ExperimentalIt binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]
AGA2115
go.drugbank.com/drugs/DB17840InvestigationalDeveloped by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.[L46646]
IMMU-114
go.drugbank.com/drugs/DB18458InvestigationalIMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.
Amedalin
go.drugbank.com/drugs/DB09188ExperimentalAmedalin is a selective norepinephrine reuptake inhibitor developed in the 1970s.
Deudextromethorphan
go.drugbank.com/drugs/DB19054Investigationalunder investigation in clinical trial NCT02153502 (Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to